| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Ganoderol A targets the cholesterol synthesis pathway, inhibiting cholesterol production. It also inhibits 5α-reductase, an enzyme involved in androgen metabolism. The compound exhibits anti-inflammatory activity and protects against UVA damage. Its molecular targets include pathways involved in cell proliferation and immune responses. Further studies are needed to fully elucidate its specific molecular targets.
|
|---|---|
| ln Vitro |
Ganoderol A demonstrates in vitro antimicrobial activities. It inhibits the cholesterol synthesis pathway in cultured cells. The compound exhibits significant anti-inflammatory activity and protection against UVA damage in vitro. It also shows anti-androgenic and anticancer activities in cell-based assays. These activities make Ganoderol A a candidate for research on skin protection, inflammation, and prostate health.
|
| ln Vivo |
In vivo activity of Ganoderol A has been suggested by its anti-inflammatory and skin-protective effects. The compound's ability to inhibit cholesterol synthesis and 5α-reductase suggests potential for in vivo studies on cardiovascular and prostate health. Further in vivo investigations are needed to fully characterize its efficacy, pharmacokinetics, and therapeutic potential.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Ganoderol A include measuring its inhibition of 5α-reductase activity using enzymatic assays. Its effects on cholesterol synthesis can be assessed using radiolabeled precursor incorporation assays or by measuring cholesterol levels in treated cells. Anti-inflammatory activity is evaluated by measuring cytokine production in activated immune cells.
|
| Cell Assay |
In vitro cellular assays for Ganoderol A involve treating cultured cells (e.g., keratinocytes, immune cells, cancer cells) with varying concentrations of the compound. Cell proliferation is assessed using MTT or other viability assays. Anti-inflammatory activity is evaluated by measuring cytokine production. Protection against UVA damage is assessed by measuring cell survival and DNA damage following UVA exposure.
|
| Animal Protocol |
In vivo animal experiments for Ganoderol A would typically involve administering the compound to animal models of inflammation, skin damage, or prostate disease. Efficacy would be evaluated by measuring inflammatory markers, tissue damage, or tumor growth. The compound's skin-protective effects could be assessed in models of UV-induced photoaging. Further in vivo studies are needed to validate its therapeutic potential.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Ganoderol A are limited. As a triterpenoid, its absorption, distribution, metabolism, and excretion properties would influence its bioavailability and therapeutic efficacy. Further pharmacokinetic studies in animal models are needed to determine its systemic exposure, half-life, and tissue distribution for potential therapeutic applications.
|
| Toxicity/Toxicokinetics |
Toxicological data for Ganoderol A are limited. As a natural product from Ganoderma lucidum, it is generally considered to have low toxicity, but comprehensive toxicological studies have not been reported. Standard laboratory safety precautions should be followed when handling this compound. It is intended for research use only.
|
| References |
|
| Additional Infomation |
Ganoderol A is a triterpenoid compound. It has been reported that Ganoderol A exists in Ganoderma lucidum and Ganoderma sinense, and relevant data are available for reference.
Ganoderol A (CAS#: 104700-97-2) is a triterpenoid from Ganoderma lucidum with antimicrobial, anti-inflammatory, and skin-protective activities. Its molecular formula is C30H46O2 with a molecular weight of 438.69. The compound inhibits cholesterol synthesis and 5α-reductase. It is used in research on inflammation, skin protection, and prostate health. |
| Molecular Formula |
C30H46O2
|
|---|---|
| Molecular Weight |
438.69
|
| Exact Mass |
438.349
|
| CAS # |
104700-97-2
|
| PubChem CID |
13934284
|
| Appearance |
White to off-white solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
550.9±50.0 °C at 760 mmHg
|
| Flash Point |
231.8±22.7 °C
|
| Vapour Pressure |
0.0±3.4 mmHg at 25°C
|
| Index of Refraction |
1.546
|
| LogP |
8.53
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
32
|
| Complexity |
873
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
C[C@H](CC/C=C(\C)/CO)[C@H]1CC[C@@]2([C@@]1(CC=C3C2=CC[C@@H]4[C@@]3(CCC(=O)C4(C)C)C)C)C
|
| InChi Key |
QWFPQDGDUOGOJF-SPFFTVLFSA-N
|
| InChi Code |
InChI=1S/C30H46O2/c1-20(19-31)9-8-10-21(2)22-13-17-30(7)24-11-12-25-27(3,4)26(32)15-16-28(25,5)23(24)14-18-29(22,30)6/h9,11,14,21-22,25,31H,8,10,12-13,15-19H2,1-7H3/b20-9+/t21-,22-,25+,28-,29-,30+/m1/s1
|
| Chemical Name |
(5R,10S,13R,14R,17R)-17-[(E,2R)-7-hydroxy-6-methylhept-5-en-2-yl]-4,4,10,13,14-pentamethyl-1,2,5,6,12,15,16,17-octahydrocyclopenta[a]phenanthren-3-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2795 mL | 11.3976 mL | 22.7951 mL | |
| 5 mM | 0.4559 mL | 2.2795 mL | 4.5590 mL | |
| 10 mM | 0.2280 mL | 1.1398 mL | 2.2795 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
